Bo Dai, MD, PhD, presented “Management of mCRPC in China” for the Grand Rounds in Urology audience in July, 2020.
Summary:
Bo Dai, MD, PhD, Chief Physician and Director of the Department of Urology at Fudan University Shanghai Cancer Center, gives an overview of how metastatic castration-resistant prostate cancer (mCRPC) is managed in China. He explains that docetaxel, abiraterone, and enzalutamide are the only treatments available in China despite the proven effectiveness of other drug treatments. He references the PROfound study, which proved the effectiveness of olaparib, an FDA-approved drug which is available for metastatic ovarian cancer, but not mCRPC as of yet. Dr. Dai also reviews unmet treatment needs, including a lack of knowledge of the optimal treatment sequence, a need for overall survival improvement in the population of mCRPC patients in China, a lack of treatment urgency, and a lack of treatment affordability. He then shares data from Chinese studies on abiraterone and GT0918, which have both been found to produce positive results in patients. Dr. Dai concludes by discussing how abiraterone has become the most common mCRPC drug treatment due to it being produced in China.
For more educational content from our Asian Series, don’t miss HIFU for Prostate Cancer in Asia with Dr. Sunao Shoji.
How to cite: Dai, Bo. “Management of mCRPC in China” July, 2020. Accessed Jul 2024. https://grandroundsinurology.com/management-of-mcrpc-in-china/
ABOUT THE AUTHOR
Dr. Dai is a chief physician and director of the Department of Urology, Fudan University Shanghai Cancer Center. He has over 20 years of treating Urological cancers.
Dr. Dai received 6 grants from national and provincial foundations, and he published more than 50 original articles in peer-reviewed journals (including EU, JU, BJUI, etc) as the first author or corresponding author. He has received numerous awards in recent years, including one for the Top Ten Young Doctors of Fudan University, the Outstanding Young Talent Training Plan of Shanghai Municipal Commission of Health and Family Planning, and the Annual influential man of Shanghai Urological Association, as well as a nomination award for Outstanding Urologist of the Shanghai Municipality.
